Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(18):1419-1420; doi:10.1093/jnci/93.18.1419
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Baz, D. V.
Right arrow Articles by Nogueira, J. A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baz, D. V.
Right arrow Articles by Nogueira, J. A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 18, 1419-1420, September 19, 2001
© 2001 Oxford University Press

CORRESPONDENCE

Irinotecan-Induced Dysarthria

David Vicente Baz, Javier Salvador Bofill, José Andrés Moreno Nogueira

Affiliation of authors: Medical Oncology Service, Hospital Universitario "Virgen del Rocío," Sevilla, Spain.

Correspondence to: David Vicente Baz, M.D., Medical Oncology Service, CDT Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot s/n, Apartado 41013, Sevilla, Spain (e-mail: vibaz@arrakis.es).

Irinotecan (CPT-11) is a semisynthetic analogue of camptothecin with antitumor activity in solid neoplasias. Camptothecin inhibits topoisomerase I and impedes the uncoiling of the DNA double helix, thus delaying its replication and cell division. Currently, CPT-11 combined with 5-fluorouracil (5-FU) is used as a first-line treatment of advanced colorectal cancer (. . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
P. Hamberg, R. C. J. M. Donders, and D. ten Bokkel Huinink
Central Nervous System Toxicity Induced by Irinotecan
J Natl Cancer Inst, February 1, 2006; 98(3): 219 - 219.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. De Marco, E. Squilloni, L. Vigna, M. F. Bertagnolio, and C. N. Sternberg
Irinotecan chemotherapy associated with transient dysarthria and aphasia
Ann. Onc., July 1, 2004; 15(7): 1147 - 1148.
[Full Text] [PDF]